Barclays PLC Checkpoint Therapeutics, Inc. Transaction History

Barclays PLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$2.68 - $4.46 $22,018 - $36,643	-8,216 Closed	0 $0
Q3 2021 Nov 09, 2021	SELL	$2.5 - $3.53 $111,082 - $156,848	-44,433 Reduced 84.39%	8,216 $27,000
Q2 2021 Aug 13, 2021	BUY	$2.36 - $3.2 $22,136 - $30,016	9,380 Added 21.68%	52,649 $156,000
Q1 2021 May 13, 2021	BUY	$2.6 - $4.16 $69,058 - $110,493	26,561 Added 158.97%	43,269 $136,000
Q4 2020 Feb 11, 2021	SELL	$2.19 - $2.96 $8,578 - $11,594	-3,917 Reduced 18.99%	16,708 $44,000
Q3 2020 Nov 12, 2020	SELL	$1.62 - $4.24 $2,844 - $7,445	-1,756 Reduced 7.85%	20,625 $55,000
Q2 2020 Aug 12, 2020	BUY	$1.19 - $2.27 $13,393 - $25,548	11,255 Added 101.16%	22,381 $45,000
Q1 2020 May 13, 2020	SELL	$1.11 - $2.43 $14,815 - $32,433	-13,347 Reduced 54.54%	11,126 $17,000
Q4 2019 Feb 10, 2020	BUY	$1.18 - $2.39 $14,646 - $29,664	12,412 Added 102.91%	24,473 $42,000
Q3 2019 Nov 14, 2019	SELL	$2.15 - $3.36 $6,015 - $9,401	-2,798 Reduced 18.83%	12,061 $30,000
Q2 2019 Aug 14, 2019	BUY	$2.75 - $5.0 $40,862 - $74,295	14,859 New	14,859 $45,000

1.91M

Ticker CKPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,497,000
Market Cap $296M
Description
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.